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Enlarging the chemical space of anti-leishmanials:
a structure–activity relationship study of peptoids
against Leishmania mexicana, a causative agent of
cutaneous leishmaniasis†‡
H. L. Bolt,§a G. A. Eggimann,§a Paul W. Denny*ab and Steven L. Cobb*a
Peptoids, a class of peptide mimetics, have emerged as promising anti-infective agents against a range of
bacterial and fungal infections. Recently we have shown peptoids to be novel anti-parasitic and, specifi-
cally, anti-leishmanial, compounds. In this study, we have expanded the chemical space of our peptoid li-
brary and have identified peptoids with low micromolar activity against Leishmania mexicana axenic
amastigotes and significantly, the first peptoids with promising activity against intracellular amastigotes,
which are the clinical cause of cutaneous leishmaniasis.
Leishmaniasis is a neglected tropical disease caused by insect
vector borne protozoan parasites and is endemic in over 80
countries worldwide. It is estimated that more than 12
million people are currently infected and over 350 million
people live at risk of infection. The vast majority of suffers
live in areas of poverty where access to health care is often
severely limited. Distinct Leishmania species can cause
different forms of the disease; cutaneous leishmaniasis (CL),
which leads to significant scaring and mucosal damage
(mucocutaneous leishmaniasis), or visceral leishmaniasis (VL)
causing life-threatening organ damage.1,2
At present, there is no vaccine available for the prevention
of CL and VL, and current treatments rely on a limited selec-
tion of drugs, such as sodium stibogluconate (Pentostam)
and meglumine antimoniate (Glucantime). These antimo-
nials, requiring reduction to the trivalent SbĲIII) form but with
an unclear mode of action, have been in clinical use for over
70 years despite showing severe side-effects and requiring
parenteral administration.3–5 Furthermore, the long usage of
pentavalent antimonials in the treatment of leishmaniasis is
leading to the emergence of drug resistance. Although resis-
tance is not yet widespread, Leishmania spp. resistance to
these drugs can be easily induced in a laboratory environ-
ment.4,5 Therefore second-line drugs such as amphotericin B
(Fungizone, a polyene antibiotic which binds parasite specific
sterols) and the aromatic diamidine pentamidine (mecha-
nism of action unclear) have been used increasingly.4,5 Both
have been in clinical use for over 30 years, share the severe
side-effects of antimonials and also require parenteral ad-
ministration. The newest and only oral drug for VL,
miltefosine (a phospholipid, originally developed as an anti-
cancer drug, with an unverified mode of action against Leish-
mania spp.), is limited by its teratogenicity.4,5 Parasitic resis-
tance towards these alternative drugs has not yet been
conclusively confirmed in the field, but there are indications
that it may only be a matter of time.4,6 Given the issues sur-
rounding the use of the current first- and second-line drugs
to treat leishmaniasis, there is clearly an urgent need to de-
velop new and effective therapies.
Recently, there has been considerable interest in the dis-
covery and development of safer, more effective treatments
for VL. In the 2012 London Declaration on neglected tropical
diseases, public and private partnerships pledged to help
control VL by 2020.7 In contrast CL, a disease that causes 1.2
million new cases each year, remains relatively ignored. Al-
though CL is usually non-fatal, it results in ulcerated lesions
that can cause severe disfigurement and lead to other signifi-
cant medical problems, disability and social exclusion.
Antimicrobial peptides (AMPs) have been proposed as one
potential solution to the development of new topical agents
to treat CL.8–11 However, their inherent chemical and biologi-
cal instability presents a major hurdle and only a few AMPs
are currently in clinical trials as anti-bacterials.12
Peptoids, a class of peptide-mimetics, offer a better oppor-
tunity for the development of new topical anti-leishmanial
therapeutics; they are cheaper to manufacture than peptide
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based drugs and are much more stable under physiological
conditions with an improved biological lifetime. The in vitro
activity of certain peptoids against both Gram-positive and
Gram-negative bacteria and other clinically relevant targets
are very similar to those of the leading AMPs. In addition,
peptoids display the hallmark broad-spectrum activity of
AMPs, suggesting a strong mechanistic similarity.13–17 We
have recently shown that peptoids (or poly-N-substituted gly-
cines) have potential as new anti-parasitic compounds
against Leishmania mexicana, the causative agent of cutane-
ous leishmaniasis.18 In this study, we identified several
peptoids with low micromolar activities, with the best ‘hit’
having an ED50 of 17 μM against axenic L. mexicana the clini-
cally relevant, mammalian stage of the parasite.
Herein, we have expanded our peptoid library to under-
take a more detailed structure–activity relationship (SAR)
study. Over 30 novel peptoids were synthesised and tested
against L. mexicana promastigotes (insect stage parasites)
and axenic amastigotes (mammalian stage parasites). Some
peptoids from this library showed improved activity com-
pared to our first library. The most promising peptoid com-
pounds were also successfully screened, for the first time,
against intracellular amastigotes (an in vitro model of dis-
ease) and their cytotoxicity investigated. Our results provide
further evidence that peptoids may be a promising new class
of anti-infectives, particularly in the search for improved
therapeutics for the treatment of cutaneous leishmanaisis.
These peptoids are both more stable to enzymatic degrada-
tion than previously analysed antimicrobial peptides, and
show more promising activity against the clinically relevant
amastigotes.8
Results and discussion
In this extended SAR study, over 30 novel compounds were
synthesised to further investigate the biological activity pro-
file of peptoids against L. mexicana. The mode of action of
peptoids is suspected to be membrane disruption so to add
diversity to this library the sequences were designed around
four motifs (see Fig. 1) with varying side chain substituents.
We chose to add a range of substituted aromatic monomers
to provide variation compared to our previous library18 and
selected those derived from commercially available amines.
In motif 1, peptoids include the subunit NxNyNy, which
was repeated two, three or four times to give 6, 9 or 12 resi-
due peptoids respectively. For Ny different aromatic building
blocks were chosen (see Fig. 1 for the structure of the side
Fig. 1 An example of the peptoids synthesised and the chemical structures of subunits used in this peptoid library. The different structural motifs
are shown to illustrate the repeating subunits in our sequences.
MedChemCommResearch Article
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
5 
M
ar
ch
 2
01
6.
 D
ow
nl
oa
de
d 
on
 3
1/
03
/2
01
6 
16
:1
7:
50
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
Med. Chem. Commun.This journal is © The Royal Society of Chemistry 2016
chains). For the positively charged building block Nx, lysine-
type amines with different side chain lengths were chosen to
study their influence on anti-leishmanial activity.
In a further iteration, as shown in Fig. 1 with motif 2
(NxNyNz), two different Ny/Nz building blocks were used
within the sequence. These residues were uncharged and ei-
ther aromatic or alkyl amines. To investigate if the sequence
specific position of Ny/Nz with their different side chains
influenced the activity, they were also placed in a co-block
manner (motif 3). In a final design (motif 4), the overall posi-
tive charge of a 12mer peptoid was reduced by replacing ei-
ther one or two charged NLys residues with the uncharged
Namy. Namy has the same molecular weight to NLys so dif-
fers only in the chemical functionality.
The peptoid library was synthesized manually on resin
with the submonomer method using a shaker (50 °C) and 15
min for each coupling or displacement step. All peptoids
were purified by RP-HPLC to obtain a library of 49 com-
pounds (for full details regarding synthesis and characteriza-
tion, please see the ESI‡). All peptoids were screened for ac-
tivity against L. mexicana promastigotes and amastigotes.
These results are shown as ED50 values in Table 1.
After having found active peptoids against the L. mexicana
parasite in an earlier library,18 other aromatic building blocks
were included within our motif of NLysNyNy (Table 1). Using
the building block Npmb in the 12mer peptoid 19, the activ-
ity against promastigotes reduced significantly by 3 fold
(ED50 = 42 μM) compared to analogues containing Nphe
(peptoid 4, ED50 = 15 μM) or Nspe (peptoid 13, ED50 = 8 μM).
The shorter 6- and 9mer versions (peptoid 21 and 20 respec-
tively) did not show any activity against the promastigotes
and no activity could be found against amastigotes for any
length of the Npmb peptoids.
In contrast, peptoids with chlorinated and fluorinated aro-
matic building blocks (Npcb, Npfb and Nmfb; peptoids
22–30) showed enhanced activity against the axenic amas-
tigotes, whilst maintaining activity against promastigotes, the
insect form of the parasite. Peptoids 22–24 have a chloro sub-
stituent in the para position of the phenyl ring (Npcb). These
were all active against the promastigotes, but only the longer
9- and 12mer (peptoids 22 and 23) also showed any activity
against the axenic amastigotes with ED50 values of 85 or
44 μM, respectively. In case of the peptoids with fluorine
atoms in the para or meta positions, only the longest 12 resi-
due peptoids showed modest toxicity against the amastigotes
(peptoid 25: ED50 = 75 μM and peptoid 28: ED50 = 69 μM).
However, fluorinated peptoids had a good efficiency against
promastigotes, with similarly low ED50 values as the non-
halogenated analogues. Even the shorter 9 residue peptoids,
26 and 29, showed anti-parasitic activity against
promastigotes in the low μM range. The short 6mers (peptoid
27 and 30) did not show any activity against either stage of
the parasite.
Our previous study18 showed an increase in activity when
the chiral Nspe residue was included within the sequence
compared to Nphe. Therefore, the chiral aromatic building
block Nspe was then combined with the fluorinated building
block Npfb in either motif 2 or 3 (peptoids 31–36). Interest-
ingly, the analogues of both motifs had similar activity
against both promastigotes and axenic amastigotes. The lon-
gest 12 residue peptoids, 31 and 34, showed very good activity
against promastigotes (ED50 values of 8 and 6 μM). This activ-
ity was similar to the Nspe-only template peptoid 13 (ED50 =
8 μM) and about 2 fold better compared to the Npfb-only
peptoid 25 (ED50 = 15 μM). However, the difference in activity
between 31/34 and 13 was very different against the axenic
amastigote form; the Nspe-Npfb-mixed peptoids 31 and 34
showed good activity (ED50 values of 27 and 21 μM respec-
tively) whereas the Nspe-only peptoid 13 was completely inac-
tive and the Npfb-only peptoid 25 showed only moderate ac-
tivity with an ED50 of 75 μM. Therefore, the combination of
two building blocks with different activities against
promastigotes and axenic amastigotes can help to improve
the overall activity against the parasite. Peptoid 34 was the
most active compound from this part of the SAR study with
ED50 values of 6 μM (promastigotes) and 21 μM (axenic
amastigotes).
The library was then extended to include sequences that
combine one aromatic residue and one residue with an alkyl
side chain within the same peptoid. These peptoids were
based on motif 2 and the monomers NnVal, NLeu and NhLeu
were used to synthesize peptoids 37–45. As shown in Table 1,
none of these peptoids showed much activity against either
lifecycle stage of L. mexicana. Only the 12 and 9 residue
peptoids containing the NhLeu building block were active
against the promastigote form, (peptoid 43 ED50 = 12 μM,
peptoid 44 ED50 = 52 μM). These results highlight that the
size and chemical functionality of residues in the motif
NxNyNz is important for anti-leishmanial efficacy.
Our previous study showed that the hydrophobicity of side
chains in the peptoid sequence influenced the anti-parasitic
activity of the compound; the shorter Nae residue signifi-
cantly increased the biological activity against the amastigote
form of the parasite compared to the NLys building block.18
To extend the SAR study, NLys residues were replaced by the
alkyl building block Namy in several sequences. In these
peptoids, the terminal –NH2 group of one or two NLys side
chains is replaced by a –CH3 group. Thus, the net positive
charge of the peptoid is reduced, but has the same molecular
weight as the NLys analogues, as shown in Table 1 (peptoids
46–49).
For most compounds in this library (peptoids 1–45), the
promastigotes are more susceptible to the peptoids than
amastigotes. We believe this is due to the large differences in
the cell surface coat of each parasite.19 However, surprisingly,
all four Namy peptoids (46–49) showed very similar activity
not only against the promastigotes, but also against the
amastigotes. For the promastigotes, ED50 values were be-
tween 8–10 μM and therefore comparable to our previous
‘hit’, peptoid 16 (ED50 = 7 μM). The activity against the
amastigotes was also in the low μM range with ED50 values
between 15–21 μM and similar to peptoid 16 (ED50 = 17 μM).
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These results suggest that the increased hydrophobicity and
reduced charge of the Namy residues can increase biological
activity compared to shorter alkyl substituents and it does
not matter if the overall positive charge is reduced by 1 or 2
or which residue is replaced.19,20
All aforementioned results discuss assays against axenic,
i.e. extracellular, cultured amastigotes. In the clinical stage of
leishmaniasis the amastigotes reside within macrophages.
Triage from these axenic assays highlighted four promising
sequences from our library that were screened against L.
mexicana infected RAW264.7 murine macrophages. The re-
sults were obtained using an assay system recently described
for screening compounds against L. donovani infected
cells,21–23 with some modifications to suit our cell lines, and
are summarised in Table 2/Fig. 2.
Peptoid 7 and 16 were chosen from our earlier study.
Peptoid 16 (NaeNspeNspe)4 was the most potent peptoid from
the previous library and showed low μM activity against both
promastigote and axenic amastigote forms of the parasite.
Peptoid 7 is an analogue of peptoid 16 and only showed
Table 1 Chemical and biological data for peptoids. For side chain abbreviations see Fig. 1. All peptoids are amidated at the C-terminus
Peptoid Sequence
ED50 (μM)
Promastigotes Amastigotes
1a (NahNpheNphe)4 21 >100
2a (NahNpheNphe)3 >100 >100
3a (NahNpheNphe)2 >100 >100
4a (NLysNpheNphe)4 15 >100
5a (NLysNpheNphe)3 >100 >100
6a (NLysNpheNphe)2 >100 >100
7a (NaeNpheNphe)4 21 >100
8a (NaeNpheNphe)3 >100 >100
9a (NaeNpheNphe)2 >100 >100
10a (NahNspeNspe)4 11 >100
11a (NahNspeNspe)3 25 >100
12a (NahNspeNspe)2 >100 >100
13a (NLysNspeNspe)4 8 >100
14a (NLysNspeNspe)3 15 >100
15a (NLysNspeNspe)2 >100 >100
16a (NaeNspeNspe)4 7 17
17a (NaeNspeNspe)3 10 >100
18a (NaeNspeNspe)2 >100 >100
19 (NLysNpmbNpmb)4 42 >100
20 (NLysNpmbNpmb)3 >100 >100
21 (NLysNpmbNpmb)2 >100 >100
22 (NLysNpcbNpcb)4 28 44
23 (NLysNpcbNpcb)3 22 85
24 (NLysNpcbNpcb)2 29 >100
25 (NLysNpfbNpfb)4 15 75
26 (NLysNpfbNpfb)3 19 >100
27 (NLysNpfbNpfb)2 >100 >100
28 (NLysNmfbNmfb)4 14 69
29 (NLysNmfbNmfb)3 17 >100
30 (NLysNmfbNmfb)2 >100 >100
31 (NLysNpfbNspe)4 8 27
32 (NLysNpfbNspe)3 13 >100
33 (NLysNpfbNspe)2 >100 >100
34 [(NLysNpfbNpfb)ĲNLysNspeNspe)]2 6 21
35 (NLysNspeNspe)ĲNLysNpfbNpfb)ĲNLysNspeNspe) 13 >100
36 (NLysNpfbNpfb)ĲNLysNspeNspe) >100 >100
37 (NLysNnValNspe)4 >100 >100
38 (NLysNnValNspe)3 >100 >100
39 (NLysNnValNspe)2 >100 >100
40 (NLysNLeuNspe)4 >100 >100
41 (NLysNLeuNspe)3 >100 >100
42 (NLysNLeuNspe)2 >100 >100
43 (NLysNhLeuNspe)4 12 >100
44 (NLysNhLeuNspe)3 52 >100
45 (NLysNhLeuNspe)2 >100 >100
46 (NamyNspeNspe)ĳ(NLysNspeNspe)]3 8 21
47 (NamyNspeNspe)2(NLysNspeNspe)2 11 16
48 [(NamyNspeNspe)ĲNLysNspeNspe)]2 10 17
49 (NLysNspeNspe)2(NamyNspeNspe)(NLysNspeNspe) 10 15
a This data was previously reported by our group18 and is included here for comparison.
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activity against promastigotes so was used as negative control
in our assay. From this study, peptoid 34 was chosen to in-
vestigate the mixed use of the aromatic building blocks Nspe
and Npfb. Peptoid 47, was chosen to examine the effect of a
reduced overall positive charge and greater hydrophobicity of
the Namy residue.
The results show that not all peptoids with activity against
axenic amastigotes can retain their activity against the intra-
cellular amastigotes. Encouragingly, peptoid 16 showed some
activity against the intracellular parasites at 5 μM, the highest
concentration measured, whilst peptoid 34 was only moder-
ately active at this concentration. However, peptoid 47, which
had the lowest ED50 value against axenic amastigotes (16
μM), was also the most active against the intracellular
amastigotes with an ED50 of 1.6 μM. Peptoid 7 was, as
expected, non-active under the concentrations tested indicat-
ing that peptoids with little activity against the axenic
amastigotes are likely to have poor activity against intra-
macrophage amastigotes.
However, it is noteworthy, and consistent with studies
from other groups,16 that peptoids with increased antimicro-
bial activity also demonstrated increased host cell cytotoxicity
(Table 2), limiting the range of concentrations studied in the
infection assays to ≤5 μM. For example, peptoids 16 and 34
demonstrated greater toxicity against the RAW264.7 macro-
phages than the intracellular (and axenic) amastigotes (ED50
> 5 vs. the intracellular parasite against ED50 of 3 μM and 5
μM respectively vs. the macrophages); and peptoid 47 is
equivalently cytotoxic to both host and parasite (ED50 of 1.7
and 1.6 respectively). Whilst further screening determine the
Table 2 Biological data for intracellular amastigote assay. Compounds tested against, L. mexicana promastigotes, axenic amastigotes, intracellular
amastigotes and also RAW264.7 macrophage cells. All peptoids are amidated at the C-terminus. For side chain abbreviations see Fig. 1
Compound Peptoid sequence
ED50 (μM)
Promastigotes Axenic amastigotes Intracellular amastigotes RAW 264.7
Amphotericin B <2 <2 0.195 >5
7 (NaeNpheNphe)4 21 >100 >5 >5
16 (NaeNspeNspe)4 7 17 >5 3
34 [(NLysNpfbNpfb)ĲNLysNspeNspe)]2 6 21 >5 5
47 (NamyNspeNspe)2(NLysNspeNspe)2 11 16 1.6 1.7
Fig. 2 Biological data for intracellular L. mexciana amastigote assay. Briefly, RAW 264.7 murine macrophages were subcultured in 96-well plates
and incubated with L. mexicana amastigotes for 24 hours. Infected macrophages were treated with selected peptoids for 24 hours then lysed with
SDS solution to release L. mexicana. Following a 48 hour incubation, parasite viability was assessed using the alamarBlue reagent. For cytotoxicity
against macrophages only, the protocol was repeated in the absence of parasites.
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toxicity of the complete library against the host cell may have
some value for future consideration of the cytotoxicity and
mode of action of peptoids, this study sought to establish the
selective nature of peptoids identified as having significant
potency against L. mexicana axenic amastigotes.
Clearly overcoming host cell cytotoxicity is a general prob-
lem for peptoids, however the fact that peptoid 47 demon-
strated low micromolar activity against L. mexciana infected
macrophages may provide a starting for studies of the antimi-
crobial and cytotoxic effects of peptoids. Despite the host cell
toxicity the data gathered from the peptoid library (and spe-
cifically peptoids 16, 34 and 47) will help to further elucidate
the key characteristics required for anti-leishmanial com-
pound development.
Conclusions
In conclusion within this study we have significantly
enlarged the peptoid activity data available for the
development of potential anti-leishmanials. Peptoid 47
(NamyNspeNspe)2(NLysNspeNspe)2 is the first peptoid pub-
lished to have activity in the low μM range against L.
mexicana promastigotes and axenic amastigotes, and also re-
tain activity against the clinically significant intra-
macrophage amastigotes. Despite evident host macrophage
cytotoxicity, 47 is a promising starting point for peptoid-
based anti-leishmanials.
Since any potential treatments for cutaneous leishmania-
sis could be formulated for topical application, a certain level
of toxicity to host cells may be acceptable. To overcome or re-
duce the toxicity against macrophages future medicinal
chemistry investigations will need to be undertaken, perhaps
to maximise delivery of the peptoid to the parasite by
optimising host cell penetration. Given that the predicted
mode of action of peptoids is plasma membrane pore-
formation or disruption17 rather than inhibition of a protein
target, the risk of development of parasite resistance is low,
conferring an advantage to this approach in treatment.
In summary, the results described provide further evi-
dence that peptoids are a promising new class of anti-infec-
tives, particularly in the search for improved topical thera-
peutics for the treatment of CL.
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